

For Immediate Release Net Revenue increases 17% to Rs 5393 crores Net Profit up 42% to Rs 1178 crores for the year

Vadodara, May 4th, 2021

Alembic Pharmaceuticals Limited reported its consolidated financial results for the period ending 31st March 2021.

Financial Highlights for the Quarter

- Net Sales for the quarter up 6% to Rs 1280 crores.
- Net Profit for the guarter up 12% to Rs 251 crores from Rs 225 crores.

Financial Highlights for the Year

- Net sales for FY21 up 17% to Rs 5393 crores against Rs 4606 crores.
- Net profit for FY21 up 42% to Rs 1178 crores from Rs 829 crores.

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said, "It was an outstanding year with the company recording its highest sales and profit ever. This was led by strong growth in the API and International Business. The operating teams worked tirelessly through the pandemic to ensure critical supplies were uninterrupted"

Operational Highlights

International Business

- International formulations grew 19% to Rs 2942 crores for FY21.
- US Generics grew 9% to Rs 2163 crores for FY21
- Ex-US International Formulations grew 57% to Rs 779 Crores for FY21.
- 13 ANDA's were filed in the quarter and 29 ANDA filings for the year.
- R&D spend at 12% of revenue or Rs 670 Crores for the year.

India Branded Formulations Business

• India branded formulations business grew 5% to Rs 1497 crores for FY21.



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229 website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123



API Business

- API business grew 38% to Rs 214 crores in the quarter and 35% to Rs 955 crores • for FY21.
- 2 DMF were filed in the quarter, Cumulative DMF fillings at 117. •

Summary of Total Revenue is as under:

(Rs in Crores)

Particulars	Q4 FY21	Q4 FY20	% Change	FY21	FY20	% Change
Formulation						
USA	475	577	-18%	2163	1976	9%
Ex- US	233	132	77%	779	497	57%
India	358	342	5%	1497	1425	5%
API	214	155	38%	955	708	35%
Total	1280	1207	6%	5393	4606	17%

Summary of Profit is as under:

(Rs in Crores)

ABIC /

Particulars	Q4 FY21	Q4 FY20	% Change	FY21	FY20	% Change
EBITDA Pre R&D	540	512	5%	2252	1815	24%
EBITDA Pre R&D %	42%	42%		42%	39%	-
EBITDA Post R&D	359	339	6%	1631	1213	35%
EBITDA Post R&D %	28%	28%		30%	26%	ARMACU
						VADODA 390 00

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229 website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123



Profit Before Tax	305	287	6%	1431	1028	39%
Net Profit after Tax	251	225	12%	1178	829	42%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at www.alembicpharmaceuticals.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Ajay Kumar Desai	Mitanshu Shah
Phone: +91 22 – 306 11681	Phone: +91 265 – 3007630
Email: ajay.desai@alembic.co.in	Email: mitanshu.shah@alembic.co.in



ALEMBIC PHARMACEUTICALS LIMITED REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229 website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123